• Product nameAnti-ERCC8 antibody
    See all ERCC8 primary antibodies
  • Description
    Rabbit polyclonal to ERCC8
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    KLH conjugated synthetic peptide between internal sequence amino acids 210-238 of Human ERCC8 (NP_000073.1).

  • Positive control
    • Mouse spleen tissue lysate


  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at 4°C (up to 6 months). Store at -20°C long term.
  • Storage bufferPreservative: 0.09% Sodium Azide
    Constituents: PBS
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesPurified through a protein A column, followed by peptide affinity purification.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Associated products


Our Abpromise guarantee covers the use of ab107290 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 44 kDa.


  • FunctionSubstrate-recognition component of the CSA complex, a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, involved in transcription-coupled nucleotide excision repair. The CSA complex (DCX(ERCC8) complex) promotes the ubiquitination and subsequent proteasomal degradation of ERCC6 in a UV-dependent manner; ERCC6 degradation is essential for the recovery of RNA synthesis after transcription-coupled repair. It is required for the recruitement of XAB2, HMGN1 and TCEA1/TFIIS to a transcription-coupled repair complex which removes RNA polymerase II-blocking lesions from the transcribed strand of active genes.
  • PathwayProtein modification; protein ubiquitination.
  • Involvement in diseaseDefects in ERCC8 are the cause of Cockayne syndrome type A (CSA) [MIM:216400]. Cockayne syndrome is a rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in mental retardation. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer.
  • Sequence similaritiesContains 5 WD repeats.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CKN1 antibody
    • Cockayne syndrome type A antibody
    • Cockayne syndrome WD repeat protein CSA antibody
    • CSA antibody
    • DNA excision repair protein ERCC-8 antibody
    • DNA excision repair protein ERCC8 antibody
    • ERCC 8 antibody
    • ERCC8 antibody
    • ERCC8_HUMAN antibody
    • excision repair cross-complementing rodent repair deficiency, complementation group 8 antibody
    see all

Anti-ERCC8 antibody images

  • Anti-ERCC8 antibody (ab107290) at 1/100 dilution + Mouse spleen tissue lysate at 35 µg

    Predicted band size : 44 kDa

References for Anti-ERCC8 antibody (ab107290)

ab107290 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab107290.
Please use the links above to contact us or submit feedback about this product.